000120173 001__ 120173
000120173 005__ 20240228135016.0
000120173 0247_ $$2doi$$a10.1186/1471-2407-14-202
000120173 0247_ $$2pmid$$apmid:24641841
000120173 0247_ $$2pmc$$apmc:PMC3995364
000120173 037__ $$aDKFZ-2017-00755
000120173 041__ $$aeng
000120173 082__ $$a610
000120173 1001_ $$aHabl, Gregor$$b0
000120173 245__ $$aIon Prostate Irradiation (IPI) - a pilot study to establish the safety and feasibility of primary hypofractionated irradiation of the prostate with protons and carbon ions in a raster scan technique.
000120173 260__ $$aLondon$$bBioMed Central$$c2014
000120173 3367_ $$2DRIVER$$aarticle
000120173 3367_ $$2DataCite$$aOutput Types/Journal article
000120173 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1491463034_28656
000120173 3367_ $$2BibTeX$$aARTICLE
000120173 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000120173 3367_ $$00$$2EndNote$$aJournal Article
000120173 520__ $$aDue to physical characteristics, ions like protons or carbon ions can administer the dose to the target volume more efficiently than photons since the dose can be lowered at the surrounding normal tissue. Radiation biological considerations are based on the assumption that the α/β value for prostate cancer cells is 1.5 Gy, so that a biologically more effective dose could be administered due to hypofractionation without increasing risks of late effects of bladder (α/β = 4.0) and rectum (α/β = 3.9).The IPI study is a prospective randomized phase II study exploring the safety and feasibility of primary hypofractionated irradiation of the prostate with protons and carbon ions in a raster scan technique. The study is designed to enroll 92 patients with localized prostate cancer. Primary aim is the assessment of the safety and feasibility of the study treatment on the basis of incidence grade III and IV NCI-CTC-AE (v. 4.02) toxicity and/or the dropout of the patient from the planned therapy due to any reason. Secondary endpoints are PSA-progression free survival (PSA-PFS), overall survival (OS) and quality-of-life (QoL).This pilot study aims at the evaluation of the safety and feasibility of hypofractionated irradiation of the prostate with protons and carbon ions in prostate cancer patients in an active beam technique. Additionally, the safety results will be compared with Japanese results recently published for carbon ion irradiation. Due to the missing data of protons in this hypofractionated scheme, an in depth evaluation of the toxicity will be created to gain basic data for a following comparison study with carbon ion irradiation.Clinical Trial Identifier: NCT01641185 (clinicaltrials.gov).
000120173 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000120173 588__ $$aDataset connected to CrossRef, PubMed,
000120173 650_7 $$0EC 3.4.21.77$$2NLM Chemicals$$aProstate-Specific Antigen
000120173 7001_ $$aHatiboglu, Gencay$$b1
000120173 7001_ $$0P:(DE-He78)621efe295db6fdfa7f9f95011a5ea943$$aEdler, Lutz$$b2$$udkfz
000120173 7001_ $$aUhl, Matthias$$b3
000120173 7001_ $$aKrause, Sonja$$b4
000120173 7001_ $$0P:(DE-HGF)0$$aRoethke, Matthias$$b5
000120173 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b6$$udkfz
000120173 7001_ $$aHadaschik, Boris$$b7
000120173 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b8$$udkfz
000120173 7001_ $$0P:(DE-HGF)0$$aHerfarth, Klaus$$b9$$eLast author
000120173 773__ $$0PERI:(DE-600)2041352-X$$a10.1186/1471-2407-14-202$$gVol. 14, no. 1, p. 202$$n1$$p202$$tBMC cancer$$v14$$x1471-2407$$y2014
000120173 909CO $$ooai:inrepo02.dkfz.de:120173$$pVDB
000120173 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)621efe295db6fdfa7f9f95011a5ea943$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000120173 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000120173 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000120173 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000120173 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000120173 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000120173 9141_ $$y2014
000120173 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC CANCER : 2015
000120173 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000120173 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000120173 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000120173 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000120173 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000120173 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000120173 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000120173 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000120173 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000120173 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000120173 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000120173 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000120173 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000120173 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000120173 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x1
000120173 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lKKE Strahlentherapie$$x2
000120173 980__ $$ajournal
000120173 980__ $$aVDB
000120173 980__ $$aI:(DE-He78)C060-20160331
000120173 980__ $$aI:(DE-He78)E010-20160331
000120173 980__ $$aI:(DE-He78)E050-20160331
000120173 980__ $$aUNRESTRICTED